

Does the underlying haemodynamic abnormality determine response to antihypertensive therapy?

Submission date 12/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 12/05/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 04/08/2016	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs Michaela Watts

Contact details
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Clinical Trials Information System (CTIS)
2006-006981-40

Protocol serial number
5293

Study information

Scientific Title

Does the underlying haemodynamic abnormality determine response to antihypertensive therapy?

Acronym

Rotation Study

Study objectives

The purpose of the study/trial is to find out the relation of haemodynamic abnormalities in 60 patients with hypertension and their responses to different classes of antihypertensive agents.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved, ref: 07/Q0108/33

Study design

Single-centre randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions

Patients will be enrolled and the following data is collected:

1. History
2. Physical examination
3. Height
4. Weight
5. Blood tests
6. Electrocardiogram (ECG)
7. Haemodynamic measurements

Administration of medications will be in a double-blind randomised placebo controlled cross-over methodology: doxazosin 1 - 4 mg, bisoprolol 2.5 - 5 mg, candesartan 8 - 16 mg, isosorbide mononitrate M/R 25 - 50 mg

There will be 42 days per treatment phase and 36 weeks in total.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Doxazosin, bisoprolol, candesartan, isosorbide mononitrate

Primary outcome(s)

Difference in BP change according to pre-specified group analysis.

Key secondary outcome(s)

1. Change in haemodynamic parameters achieved by different study medication
2. Number of patients reaching target BP

Completion date

01/08/2009

Eligibility

Key inclusion criteria

Hypertensive patients

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/06/2007

Date of final enrolment

01/08/2009

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Addenbrookes Hospital
Cambridge

United Kingdom
CB2 2QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (BHF) (UK)

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
	results				

[Results article](#)

01/01/2014

Yes

No